Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy

Astha Thakkar; Kith Pradhan; Shawn Jindal; Zhu Cui; Bradley Rockwell; Akash Pradip Shah; Stuart Packer; R. Alejandro Sica; Joseph Sparano; D. Yitzhak Goldstein; Amit Verma; Sanjay Goel; Balazs Halmos

doi:10.1038/s43018-021-00191-y

Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy

Astha Thakkar, Kith Pradhan, Shawn Jindal, Zhu Cui, Bradley Rockwell, Akash Pradip Shah, Stuart Packer, R. Alejandro Sica, Joseph Sparano, D. Yitzhak Goldstein, Amit Verma, Sanjay Goel, Balazs Halmos

Research output: Contribution to journal › Article › peer-review

86 Scopus citations

Abstract

Patients with cancer have been identified in several studies to be at high risk of developing severe COVID-19; however, rates of SARS-CoV-2 IgG seroconversion and its association with cancer types and anticancer therapy remain obscure. We conducted a retrospective cohort study in patients with cancer who underwent SARS-CoV-2 IgG testing. Two hundred and sixty-one patients with a cancer diagnosis underwent SARS-CoV-2 IgG testing and demonstrated a high rate of seroconversion (92%). However, significantly lower seroconversion was observed in patients with hematological malignancies (82%), patients who received anti-CD-20 antibody therapy (59%) and stem cell transplant (60%). Notably, all 17 patients who received immunotherapy, including 16 that received anti-PD-1/PD-L1 monoclonal antibodies, developed SARS-CoV-2 IgG antibodies (100% seroconversion). These data show differential rates of seroconversion in specific patient groups and bear importance for clinical monitoring and vaccination strategies that are being developed to mitigate the COVID-19 pandemic.

Original language	English (US)
Pages (from-to)	392-399
Number of pages	8
Journal	Nature Cancer
Volume	2
Issue number	4
DOIs	https://doi.org/10.1038/s43018-021-00191-y
State	Published - Apr 2021

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s43018-021-00191-y

Cite this

@article{310e043d943a411d9d86ca8d39d8857c,

title = "Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy",

abstract = "Patients with cancer have been identified in several studies to be at high risk of developing severe COVID-19; however, rates of SARS-CoV-2 IgG seroconversion and its association with cancer types and anticancer therapy remain obscure. We conducted a retrospective cohort study in patients with cancer who underwent SARS-CoV-2 IgG testing. Two hundred and sixty-one patients with a cancer diagnosis underwent SARS-CoV-2 IgG testing and demonstrated a high rate of seroconversion (92%). However, significantly lower seroconversion was observed in patients with hematological malignancies (82%), patients who received anti-CD-20 antibody therapy (59%) and stem cell transplant (60%). Notably, all 17 patients who received immunotherapy, including 16 that received anti-PD-1/PD-L1 monoclonal antibodies, developed SARS-CoV-2 IgG antibodies (100% seroconversion). These data show differential rates of seroconversion in specific patient groups and bear importance for clinical monitoring and vaccination strategies that are being developed to mitigate the COVID-19 pandemic.",

author = "Astha Thakkar and Kith Pradhan and Shawn Jindal and Zhu Cui and Bradley Rockwell and Shah, {Akash Pradip} and Stuart Packer and Sica, {R. Alejandro} and Joseph Sparano and Goldstein, {D. Yitzhak} and Amit Verma and Sanjay Goel and Balazs Halmos",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.",

year = "2021",

month = apr,

doi = "10.1038/s43018-021-00191-y",

language = "English (US)",

volume = "2",

pages = "392--399",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

number = "4",

}

TY - JOUR

T1 - Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy

AU - Thakkar, Astha

AU - Pradhan, Kith

AU - Jindal, Shawn

AU - Cui, Zhu

AU - Rockwell, Bradley

AU - Shah, Akash Pradip

AU - Packer, Stuart

AU - Sica, R. Alejandro

AU - Sparano, Joseph

AU - Goldstein, D. Yitzhak

AU - Verma, Amit

AU - Goel, Sanjay

AU - Halmos, Balazs

PY - 2021/4

Y1 - 2021/4

N2 - Patients with cancer have been identified in several studies to be at high risk of developing severe COVID-19; however, rates of SARS-CoV-2 IgG seroconversion and its association with cancer types and anticancer therapy remain obscure. We conducted a retrospective cohort study in patients with cancer who underwent SARS-CoV-2 IgG testing. Two hundred and sixty-one patients with a cancer diagnosis underwent SARS-CoV-2 IgG testing and demonstrated a high rate of seroconversion (92%). However, significantly lower seroconversion was observed in patients with hematological malignancies (82%), patients who received anti-CD-20 antibody therapy (59%) and stem cell transplant (60%). Notably, all 17 patients who received immunotherapy, including 16 that received anti-PD-1/PD-L1 monoclonal antibodies, developed SARS-CoV-2 IgG antibodies (100% seroconversion). These data show differential rates of seroconversion in specific patient groups and bear importance for clinical monitoring and vaccination strategies that are being developed to mitigate the COVID-19 pandemic.

AB - Patients with cancer have been identified in several studies to be at high risk of developing severe COVID-19; however, rates of SARS-CoV-2 IgG seroconversion and its association with cancer types and anticancer therapy remain obscure. We conducted a retrospective cohort study in patients with cancer who underwent SARS-CoV-2 IgG testing. Two hundred and sixty-one patients with a cancer diagnosis underwent SARS-CoV-2 IgG testing and demonstrated a high rate of seroconversion (92%). However, significantly lower seroconversion was observed in patients with hematological malignancies (82%), patients who received anti-CD-20 antibody therapy (59%) and stem cell transplant (60%). Notably, all 17 patients who received immunotherapy, including 16 that received anti-PD-1/PD-L1 monoclonal antibodies, developed SARS-CoV-2 IgG antibodies (100% seroconversion). These data show differential rates of seroconversion in specific patient groups and bear importance for clinical monitoring and vaccination strategies that are being developed to mitigate the COVID-19 pandemic.

UR - http://www.scopus.com/inward/record.url?scp=85103208370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103208370&partnerID=8YFLogxK

U2 - 10.1038/s43018-021-00191-y

DO - 10.1038/s43018-021-00191-y

M3 - Article

C2 - 34661163

AN - SCOPUS:85103208370

SN - 2662-1347

VL - 2

SP - 392

EP - 399

JO - Nature Cancer

JF - Nature Cancer

IS - 4

ER -

Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this